Table 3. Prognostic factors for locoregional failure-free survival (LRFFS) and overall survival (OS).

	LRFFS
		UVA			MVA
Characteristic	HR	95% CI	P	HR	95% CI	P
Age, years (< 65 vs. ≥65)	1.258	0.85–1.87	0.258
Sex (male vs. female)	0.917	0.61–1.38	0.674
Diabetes mellitus (no vs. yes)	1.014	0.67–1.53	0.947
ECOG performance status (0 vs. 1)	1.58	1.06–2.35	0.023	1.315	0.86–2.01	0.206
Preop CA 19–9 (< 200 U/mL vs. ≥200 U/mL)	2.02	1.35–3.02	<0.001	1.738	1.04–2.92	0.037
Postop CA 19–9 (< 40 U/mL vs. ≥40 U/mL)	1.789	1.15–2.79	0.01	0.996	0.57–1.73	0.99
Tumor size (< 3cm vs. ≥3cm)	0.756	0.50–1.14	0.185
T stage (T1-2 vs. T3-4)	1.932	1.03–3.64	0.041	1.048	0.48–2.31	0.908
N stage (N0 vs. N1)	2.412	1.60–3.64	<0.001	1.661	1.03–2.69	0.04
Grade (WD-MD vs. PD-UD)	0.953	0.48–1.90	0.891
LVI (no vs. yes)	1.643	1.09–2.48	0.018	1.134	0.72–1.79	0.589
PNI (no vs. yes)	1.975	1.28–3.06	0.002	1.813	1.09–3.01	0.021
Resection margin (R0 vs. R1)	2.101	1.14–3.87	0.017	1.99	1.04–3.81	0.037
PNE (no vs. yes)	2.547	1.53–4.23	<0.001	1.57	0.88–2.82	0.13
Chemotherapy (no vs. yes)	1.053	0.70–1.59	0.805
	OS
		UVA			MVA
Characteristic	HR	95% CI	P	HR	95% CI	P
Age, years (< 65 vs. ≥65)	1.648	1.06–2.56	0.027	1.489	0.94–2.37	0.093
Sex (male vs. female)	0.93	0.60–1.45	0.749
Diabetes mellitus (no vs. yes)	0.947	0.60–1.50	0.816
ECOG performance status (0 vs. 1)	1.373	0.89–2.13	0.157
Preop CA 19–9 (< 200 U/mL vs. ≥200 U/mL)	1.891	1.22–2.94	0.005	1.375	0.77–2.45	0.28
Postop CA 19–9 (< 40 U/mL vs. ≥40 U/mL)	2.034	1.26–3.29	0.004	1.289	0.72–2.33	0.398
Tumor size (< 3cm vs. ≥3cm)	0.829	0.53–1.30	0.416
T stage (T1-2 vs. T3-4)	1.658	0.87–3.16	0.125
N stage (N0 vs. N1)	2.439	1.55–3.83	<0.001	1.897	1.15–3.13	0.012
Grade (WD-MD vs. PD-UD)	0.943	0.43–2.06	0.883
LVI (no vs. yes)	1.911	1.21–3.02	0.006	1.413	0.85–2.34	0.181
PNI (no vs. yes)	2.011	1.25–3.25	0.004	1.838	1.08–3.12	0.024
Resection margin (R0 vs. R1)	2.305	1.18–4.51	0.015	2.113	1.02–4.36	0.043
PNE (no vs. yes)	2.165	1.20–3.92	0.011	1.13	0.57–2.26	0.729
Chemotherapy (no vs. yes)	0.978	0.62–1.53	0.921